Literature DB >> 18264833

Predicting survival in potentially curable lung cancer patients.

Thida Win1, Linda Sharples, Ashley M Groves, Andrew J Ritchie, Francis C Wells, Clare M Laroche.   

Abstract

Lung cancer is the most common cause of cancer death with unchanged mortality for 50 years. Only localized nonsmall-cell lung cancer (NSCLC) is curable. In these patients it is essential to accurately predict survival to help identify those that will benefit from treatment and those at risk of relapse. Despite needing this clinical information, prospective data are lacking. We therefore prospectively identified prognostic factors in patients with potentially curable lung cancer. Over 2 years, 110 consecutive patients with confirmed localized NSCLC (stages 1-3A) were recruited from a single tertiary center. Prognostic factors investigated included age, gender, body mass index (BMI), performance status, comorbidity, disease stage, quality of life, and respiratory physiology. Patients were followed up for 3-5 years and mortality recorded. The data were analyzed using survival analysis methods. Twenty-eight patients died within 1 year, 15 patients died within 2 years, and 11 patients died within 3 years postsurgery. Kaplan-Meier survival estimates show a survival rate of 51% at 3 years. Factors significantly (p < 0.05) associated with poor overall survival were age at assessment, diabetes, serum albumin, peak VO(2) max, shuttle walk distance, and predicted postoperative transfer factor. In multiple-variable survival models, the strongest predictors of survival overall were diabetes and shuttle walk distance. The results show that potentially curable lung cancer patients should not be discriminated against with respect to weight and smoking history. Careful attention is required when managing patients with diabetes. Respiratory physiologic measurements were of limited value in predicting long-term survival after lung cancer surgery.

Entities:  

Mesh:

Year:  2008        PMID: 18264833     DOI: 10.1007/s00408-007-9067-1

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  15 in total

1.  Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses.

Authors:  K Suzuki; K Nagai; J Yoshida; M Nishimura; K Takahashi; T Yokose; Y Nishiwaki
Journal:  Cancer       Date:  1999-11-15       Impact factor: 6.860

2.  Ventilation-perfusion scintigraphy to predict postoperative pulmonary function in lung cancer patients undergoing pneumonectomy.

Authors:  Thida Win; Angela D Tasker; Ashley M Groves; Carol White; Andrew J Ritchie; Francis C Wells; Clare M Laroche
Journal:  AJR Am J Roentgenol       Date:  2006-11       Impact factor: 3.959

3.  Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA.

Authors:  M T van Rens; A B de la Rivière; H R Elbers; J M van Den Bosch
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

4.  The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years.

Authors:  Roy Båtevik; Ketil Grong; Leidulf Segadal; Lodve Stangeland
Journal:  Lung Cancer       Date:  2005-02       Impact factor: 5.705

5.  Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients.

Authors:  Joachim Pfannschmidt; Thomas Muley; Heinrich Bülzebruck; Hans Hoffmann; Hendrik Dienemann
Journal:  Lung Cancer       Date:  2006-11-22       Impact factor: 5.705

6.  Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study.

Authors:  Tomoyuki Goya; Hisao Asamura; Hirokuni Yoshimura; Harubumi Kato; Kaoru Shimokata; Ryosuke Tsuchiya; Yasunori Sohara; Toshimichi Miya; Etsuo Miyaoka
Journal:  Lung Cancer       Date:  2005-08-02       Impact factor: 5.705

7.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

8.  Surgical results of stage I non-small cell lung cancer: comparison between elderly and younger patients.

Authors:  Kazumichi Yamamoto; José Padilla Alarcón; Victor Calvo Medina; Angel García-Zarza; Juan Pastor Guillen; Eduardo Blasco Armengod; Francisco París Romeu
Journal:  Eur J Cardiothorac Surg       Date:  2003-01       Impact factor: 4.191

9.  Development of a shuttle walking test of disability in patients with chronic airways obstruction.

Authors:  S J Singh; M D Morgan; S Scott; D Walters; A E Hardman
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

10.  The physiologic evaluation of patients with lung cancer being considered for resectional surgery.

Authors:  Michael A Beckles; Stephen G Spiro; Gene L Colice; Robin M Rudd
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

View more
  14 in total

1.  Body mass index and mortality in lung cancer patients: a systematic review and meta-analysis.

Authors:  J Wang; H Xu; S Zhou; D Wang; L Zhu; J Hou; J Tang; J Zhao; S Zhong
Journal:  Eur J Clin Nutr       Date:  2017-05-17       Impact factor: 4.016

2.  Annexin A2 silencing induces G2 arrest of non-small cell lung cancer cells through p53-dependent and -independent mechanisms.

Authors:  Chi-Yun Wang; Chia-Ling Chen; Yau-Lin Tseng; Yi-Ting Fang; Yee-Shin Lin; Wu-Chou Su; Chien-Chin Chen; Kung-Chao Chang; Yi-Ching Wang; Chiou-Feng Lin
Journal:  J Biol Chem       Date:  2012-08-02       Impact factor: 5.157

Review 3.  Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  Nutr J       Date:  2010-12-22       Impact factor: 3.271

4.  TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients.

Authors:  M J Pajares; J Agorreta; E Salvo; C Behrens; I I Wistuba; L M Montuenga; R Pio; A Rouzaut
Journal:  Br J Cancer       Date:  2014-01-30       Impact factor: 7.640

5.  Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.

Authors:  Satoshi Ikeda; Hiroshige Yoshioka; Satoshi Ikeo; Mitsunori Morita; Naoyuki Sone; Takashi Niwa; Akihiro Nishiyama; Toshihide Yokoyama; Akimasa Sekine; Takashi Ogura; Tadashi Ishida
Journal:  BMC Cancer       Date:  2017-11-28       Impact factor: 4.430

6.  A nomogram based on serum bilirubin and albumin levels predicts survival in gastric cancer patients.

Authors:  Huiling Sun; Bangshun He; Zhenlin Nie; Yuqin Pan; Kang Lin; Hongxin Peng; Tao Xu; Xiaoxiang Chen; Xiuxiu Hu; Zijuan Wu; Di Wu; Shukui Wang
Journal:  Oncotarget       Date:  2017-06-20

7.  Low Body Mass Index Is an Independent Predictive Factor after Surgical Resection in Patients with Non-Small Cell Lung Cancer

Authors:  Masaki Tomita; Takanori Ayabe; Kunihide Nakamura
Journal:  Asian Pac J Cancer Prev       Date:  2017-12-29

8.  Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer.

Authors:  Samantha F Ehrlich; Charles P Quesenberry; Stephen K Van Den Eeden; Jun Shan; Assiamira Ferrara
Journal:  Diabetes Care       Date:  2009-10-06       Impact factor: 19.112

9.  Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer.

Authors:  Ying Jin; Li Zhao; Fang Peng
Journal:  Clinics (Sao Paulo)       Date:  2013-05       Impact factor: 2.365

Review 10.  The Effect of Diabetes Mellitus on Lung Cancer Prognosis: A PRISMA-compliant Meta-analysis of Cohort Studies.

Authors:  Linhai Zhu; Hongxin Cao; Tiehong Zhang; Hongchang Shen; Wei Dong; Liguang Wang; Jiajun Du
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.